Personalizing Prophylaxis for Hemophilia A and B: A New Era in Treatment and Management

Friday, February 26, 2021, 8:00 AM - Friday, February 25, 2022, 11:59 PM

AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.

1. Identify the barriers and challenges associated with the management of hemophilia A and hemophilia B;
2. Evaluate the clinical data of extended half-life factors and newer strategies to traditional replacement therapies and their potential to result in improved outcomes;
3. Develop a strategy for how to incorporate EHL and newer strategies as part of an individualized approach to prophylactic management of hemophilia.

There are no fees for participating in and receiving CME credit for this online activity.

To participate in this activity, register with ReachMD.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CME FRONT MATTER

Faculty & Disclosure / Conflict of Interest Policy

According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Medical Director & Program Planners

CORE Medical Education, LLC
Otto Ratz, MD
Christina Culbert, MSc

CORE Medical Education staff have no relevant conflict of interest to report.

University of Cincinnati Continuing Medical Education Office
Bruce Gebhardt, MD, Professor, Physician Reviewer
Susan P. Tyler, PhD, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

University of Cincinnati staff have no relevant conflict of interest to report.

Disclaimer Statement
The opinions expressed during the endured activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

 

Steven W. Pipe, MD, Professor of Pediatrics and Pathology, University of Michigan, disclosed the following relationships:  Apcintex, Bayer, Biomarink, Catalyst Biosciences, CSL, Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genetech, Sangamo Therapeurtics, Sanofi, Takeda, Spark Therapeutics, and uniQure (Consultant); Siemens (Research)

John R. Russell, MD, Program Host, ReachMD, disclosed the following relationships: Sanofi Pasteur (Advisory Board; Speaker's Bureau); GlaxoSmithKline (Advisory Board; Consultant)

This program is supported by an educational grant from Sanofi US and Novo Nordisk, Inc.